GPC Appoint Chairman of SAB

Source Press Release
Company RocheGPC BiotechAltanaStreamlineFranklin MedicalPathology 
Tags Personnel
Date January 27, 1999

Munich, Germany -- January 27, 1999 -- GPC AG - Genome Pharmaceuticals Corporation, a genomics-based drug discovery company, today announced the appointment of Prof. Dr. Jürgen Drews as Chairman of the Scientific Advisory Board and Chief Strategic Advisor in addition to his membership on the Board of Directors.

Until his recent retirement, Prof. Dr. Drews held the position of President of Global Research at Hoffmann-La Roche  and was a member of the  Roche  Group Executive Committee. He continues to take an active role in the biotech industry as demonstrated by his position as Chairman of the Board & Partner of BiOMEDiCiNE, International Biomedicine Management Partners Inc. and Chairman of the European Association for Bioindustries (EuropaBio). Prof. Dr. Drews also serves on the Board of Directors of several biotech companies.

Prof. Dr. Bernd Seizinger, GPC's Chief Executive Officer said, "We are very pleased to be able to draw upon the experience of Prof. Dr. Jürgen Drews whose comprehensive scientific, pharmaceutical and strategic expertise is highly regarded in the industry. Prof. Drews' role as Chief Strategic Advisor will be invaluable to the development of our internal drug discovery programs and will aid GPC's ability to form major pharmaceutical alliances. I am delighted that Prof Drews will also be joining GPC’s team of world-class scientific and pharmaceutical experts on our Scientific Advisory Board. His leadership will guide GPC in its scientific objectives and in ensuring the company's scientific success."

Prof. Dr. Jürgen Drews said, "I am impressed by the outstanding quality of people, science and vision at GPC and am very pleased to actively support and advise GPC in its mission to become a leader in the integration of second generation genomics technologies for the discovery and development of innovative drugs."

GPC has uniquely integrated platforms of automated and proprietary high-throughput functional genomics technologies (OliCodeTM, ExpressCodeTM PathCodeTM, BioChipExplorerTM) to streamline the process of target identification and validation. In its internal research efforts, GPC's biology teams are initially focusing on infectious diseases and diseases of the immune system. The Company is also applying its technology platforms in its existing research alliance with the Altana  subsidiary Byk Gulden, in the fields of Helicobacter pylori and Chlamydia pneunomiae. The Company’s goal is to assist major pharmaceutical companies in the process of drug discovery and development as well as to expand its technology base and build an integrated drug discovery company.

GPC's Scientific Advisory Board currently consists of:

Prof. Dr. George Church  - Professor of Genetics and Director, Lipper Center for Computational Genetics, Harvard Medical School;

Prof. Dr. Rainer Haas - Head of the Helicobacter pylori Group, Max von Pettenkofer Institute for Hygiene and Medical Microbiology;

Prof. Dr. Hans Lehrach -  Director and Head of Department, Max-Planck Institute for Molecular Genetics; Director, Resource Centre and Primary Database of the German Genome Project;

Prof. Dr.  Annemarie Poustka - Head of the Department of Molecular Genome Analysis, German Cancer Research Centre DKFZ; Director of the Resource Centre and Screening Centre of the German Genome Project;

Dr. John Sgouros -  Head  of the Computational Genome Analysis Unit at the Imperial Cancer Research Fund;

Prof. Dr. Harald Stein - Director, Institute for Pathology, Benjamin Franklin Medical Center, Free University of Berlin; and

Dr. Erich Wanker - Head of the Huntington's group, Max-Plank-Institute for Molecular Genetics.

Source: Evaluate™
©2018 Evaluate Ltd, All rights reserved.